Delisted
Stopped trading. Last price we have: $0.0500 on Apr 1, 2026. Fund positions aren't valued until we confirm what happened.
TRANSLATE BIO INC
TBIO·89374L104·UN·Common Stock·Healthcare - Medical Devices
TBIO (TRANSLATE BIO INC) is held by 0 institutional investors as of Q3 2021.
0
Holders
$0
Total Value
0%
Consensus
13F: Insider & Congress: Updated regularly
No verdict yet — fewer than 2 funds hold TBIO.
Top Holders
Checking access…
| Action | ||||||
|---|---|---|---|---|---|---|
Exited | 0(-100.0%) | $5.5M | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $234,000 | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $454,000 | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $120,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $513,200 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $5.1M | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $224,000 | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $813,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $3M | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $3.7M | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $829,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $2.3M | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $1M | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $3.4M | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $14,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $489,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $733,000 | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $735,000 | 0.0% | -43.92% | 0 | |
Exited | 0(-100.0%) | $639,000 | 0.0% | — | 0 | |
Exited | 0(-100.0%) | $73,000 | 0.0% | -43.92% | 0 |
Showing 1-20 of 73
1 / 4
TBIOTRANSLATE BIO INCContinue exploring
Other Healthcare stocks held by institutions
UNHUnitedHealth Group Inc416 holders · $299.1B
LLYEli Lilly & Co415 holders · $877.5B
TMOThermo Fisher Scientific Inc400 holders · $151.4B
JNJJohnson & Johnson397 holders · $414.1B
DHRDanaher Corp394 holders · $97.5B
ISRGIntuitive Surgical Inc393 holders · $111.5B
MRKMerck & Co Inc390 holders · $230.1B
ABBVAbbVie Inc385 holders · $302.9B
BSXBoston Scientific Corp385 holders · $51.8B
ABTAbbott Laboratories382 holders · $113.8B
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer